A nationally-published, award-winning journalist, Alex Biese joined the CURE team as an assistant managing editor in April 2023. Prior to that, Alex's work was published in outlets including the Chicago Sun-Times, MTV.com, USA TODAY and the Press of Atlantic City. Alex is a member of NLGJA: The Association of LGBTQ+ Journalists, and also performs at the Jersey Shore with the acoustic jam band Somewhat Relative.
Enrollment Continues in Study Evaluating ONCT-534 For Advanced Prostate Cancer
January 11th 2024Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).
FDA Accepts sBLA For Tivdak In Recurrent or Metastatic Cervical Cancer
January 9th 2024The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
Rare Immune Cell May Predict Immunotherapy Response in Melanoma
January 7th 2024Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.
‘Remarkable’ Results from Tecartus in Patients With R/R MCL
January 4th 2024Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.
Nurses ‘Bridge the Gap’ Between Patients, Doctors to Talk End-of-Life Care
December 22nd 2023One expert explained how nurses have “opportunities to get to talk with patients and their loved ones in ways that you don't (get) when you're in the time crunch of an appointment with your oncologist,” and how that can impact end-of-life care.
Chemo Led to Worse Survival, Response and Progression in R/R LBCL With CAR-T
December 21st 2023Patients with relapsed/refractory large B-cell lymphoma treated with CAR-T cell therapy and bendamustine chemotherapy, experienced lower rates of survival and response as well as shorter times until progression, according to recent study findings.
What Patients With Prostate Cancer Should Know About the EMBARK Trial
December 18th 2023Dr. Stephanie Berg of the Dana-Farber Cancer Institute and Harvard Medical School discussed the recent EMARK trial which resulted in the FDA’s approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis.
Giuliana Rancic Talks Breast Cancer Survivorship Insights
December 16th 2023“I have found many survivors to be very strong women who seem like they have things under control but it’s always important for family and friends to check in,” television personality, author and breast cancer survivor Giuliana Rancic told CURE.
Cancer Vaccine Plus Keytruda Reduces Risk of Recurrence or Death in Melanoma
December 15th 2023Patients with advanced-stage melanoma continue to experience reduced risk of recurrence or death following treatment with a combination of mRNA vaccine mRNA-4157 (V940) and Keytruda, an anti-PD-1 therapy, according to recent study findings.